Cimzia results elicit UCB in psoriatic arthritis InPharm UCB will refer regulatory applications for Cimzia in psoriatic arthritis by end of 2012, after positive Phase III legal proceeding results for the drug. Results from the Cimzia study showed that patients with adult onset progressive psoriatic arthritis had type A ... Positive top-line effect for UCB's Cimzia in psoriatic arthritis PharmaLive.com (press release) all 6 tidings articles » Link To Article
No comments:
Post a Comment